Physician profile
Chad E Bates
NPI 1003926353
$2,303.89
in general payments reported to CMS, 2019-2025
27 companies · $617 in 2025
The $617 reported for 2025 was more than what 77% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $113 · 2020: $162 · 2021: $196 · 2022: $315 · 2023: $509 · 2024: $393 · 2025: $617.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,519.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,519.02 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $446.85 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Abbvie INC. | $406.26 | 2021-2025 | Vraylar, Qulipta, Ubrelvy |
| Novartis Pharmaceuticals Corporation | $244.17 | 2021-2023 | |
| Glaxosmithkline, LLC. | $174.30 | 2019-2025 | Arexvy, Trelegy Ellipta, Shingrix |
| Astellas Pharma US INC | $158.16 | 2019-2025 | Veozah |
| Astrazeneca Pharmaceuticals Lp | $127.15 | 2020-2025 | Breztri, Airsupra |
| Pfizer INC. | $102.12 | 2019-2025 | |
| Dexcom, INC. | $78.85 | 2023-2024 | Dexcom G6 Transmitter |
| E.R. Squibb & Sons, L.L.C. | $59.69 | 2022-2024 | Camzyos, Eliquis |
| Merck Sharp & Dohme LLC | $59.52 | 2022-2025 | Vaxneuvance, Capvaxive, M-M-R II |
| Sanofi-Aventis U.S. LLC | $50.57 | 2022-2023 | |
| Bayer Healthcare Pharmaceuticals INC. | $49.17 | 2021-2023 | |
| Amarin Pharma, INC. | $37.76 | 2021 | |
| Ardelyx, INC. | $37.02 | 2024-2025 | Ibsrela |
| Lilly USA, LLC | $35.01 | 2024-2025 | Mounjaro, Zepbound |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Nestle Healthcare Nutrition INC. | $32.10 | 2021-2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $31.59 | 2021-2022 | |
| Sumitomo Pharma America, INC. | $20.88 | 2023 | Gemtesa |
| Horizon Therapeutics Plc | $20.48 | 2023 | Tepezza |
| Philips North America LLC | $19.89 | 2024 | (Ck7) Extended Holter |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $18.46 | 2025 | Caplyta |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $18.21 | 2020 | |
| Lundbeck LLC | $16.48 | 2022 | |
| Boston Scientific Corporation | $15.60 | 2025 | Bodyguardian |
| Janssen Pharmaceuticals, INC | $15.03 | 2019 | |
| Otsuka America Pharmaceutical, INC. | $14.96 | 2024 | Rexulti |
| Amgen INC. | $13.61 | 2025 | Krystexxa |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Chad Bates listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.